CECOG Academy

www.cecog.org

 

CECOG Academy
Avatar

How to Pick the Individual (Neo)adjuvant Treatment Concept in Resectable PAC

By CECOG Academy FEATURING Eric Van Cutsem
By CECOG Academy FEATURING Eric Van Cutsem
0 views
September 6, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Pancreas Cancer Academy 2022
10:15
CECOG Academy

Case Review of a 78 y/o Man With PDAC: Following OS From the Start o…

Feat. F. Huemer
14:55
CECOG Academy

Case Review: Fit Patient With mPDAC

Feat. H. Taghizadeh
18:58
CECOG Academy

1L mPDAC & Sequence Debate: Why Gemcitabine & Nab-Paclitaxel…

Feat. H. Wasan
18:36
CECOG Academy

mPDAC Treatment Debate: FOLFIRINOX Followed by Gemcitabine + Nab-Pac…

Feat. J. Taieb
23:12
CECOG Academy

mPDAC Sequence Debate: Albumin-Bound Paclitaxel / Gemcitabine Follow…

Feat. G. Prager
26:54
CECOG Academy

New 2022 ESMO Guidelines for Pancreatic Cancer

Feat. T. Conroy
08:41
CECOG Academy

Case Review: Borderline Resectable PDAC

Feat. H. Taghizadeh
22:45
CECOG Academy

Borderline PDAC: What Is the Best Neoadjuvant Treatment Concept?

Feat. T. Macarulla
17:52
CECOG Academy

What to Do With PDAC Patients After Secondary Resection?

Feat. H. Wasan
31:42
CECOG Academy

How to Assess Resectability: The Surgeon's View

Feat. O. Strobel
23:05
CECOG Academy

How to Pick the Individual (Neo)adjuvant Treatment Concept in Resect…

Feat. E. Van Cutsem
27:28
CECOG Academy

Personalized Treatment Approach by Molecular Profiling Might Lead to…

Feat. T. Golan